Fort Worth, TXNCT07791043Now EnrollingIRB Ready

Liver Diseases, Alcoholic Clinical Trial in Fort Worth, TX

Access cutting-edge liver diseases, alcoholic treatment through this phase 2 clinical trial at a research site in Fort Worth. Study-provided care at no cost to qualified participants.

Sponsored by GlaxoSmithKline

Quick Self-Assessment

See if you qualify for this Fort Worth location

Preparing your pre-screening questions…

Expert Care in Fort Worth

Access liver diseases, alcoholic specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related liver diseases, alcoholic treatment provided free

Apply for This Fort Worth Location

Check if you qualify for this liver diseases, alcoholic clinical trial in Fort Worth, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Fort Worth

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Fort Worth site if eligible
  4. 4Begin participation

About This Liver Diseases, Alcoholic Study in Fort Worth

This is a dose-ranging study to evaluate safety of efimosfermin alfa and to establish proof-of-concept that efimosfermin alfa therapy provides benefit in participants with ALD.

Sponsor: GlaxoSmithKline

Who Can Participate

Inclusion Criteria

Participant must be 18 to 75 years of age inclusive, at the time of Screening.
Capable of giving signed informed consent prior to the performance of any study-specific procedures.
Able and willing to comply with all study assessments and adhere to the protocol schedule of activities.
History of heavy alcohol consumption for greater than 6 months at any time prior to Screening.
A female participant is eligible to participate if they are not pregnant or breastfeeding, and one of the following conditions applies:
Is a Participant of non-childbearing potential (PONCBP) OR
Is a Participant of childbearing potential (POCBP) and using a contraceptive method that is highly effective, with a failure rate of less than (\<)1 percentage (%), 30 days prior to and during the study intervention period and for at least 16 weeks after the last dose of study intervention.

Exclusion Criteria

Other primary causes of liver disease (e.g., viral hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, drug-induced hepatotoxicity, Wilson disease, hemochromatosis, alpha-1-antitryspin deficiency, etc.). Alcohol must be the primary cause of liver disease.
Co-infection with Hepatitis B virus (HBV), Hepatitis C virus (HCV), or Human immunodeficiency virus (HIV) as indicated from the central lab
History of diabetes mellitus (DM), either:
Type 2 DM with unstable glycemic control or with major complications.
History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the 3 years prior to Screening 1, regardless of any evidence of local recurrence or metastasis.
Current, or history of known hepatocellular carcinoma (HCC).
Any major surgery within 3 months prior to Screening 1 or planned during the study
Any surgical or medical condition that might jeopardize the individual's safety or compliance with study procedures in the opinion of the investigator.
All organ transplant recipients, except for history of corneal transplants, or current listing or active consideration for liver transplant during the Screening period.
Poorly controlled hypertension.
Evidence of Wernicke-Korsakoff syndrome or alcohol-related dementia.
Prior use of a Fibroblast growth factor 21 (FGF21) analogue, including efimosfermin, within the 6 months prior to Screening 1.
Individuals with a history of resmetirom use within 3 months prior to Day 1 are to be excluded.
Concomitant use of investigational drugs for Metabolic dysfunction-associated steatohepatitis (MASH) or ALD.
Current or planned participation in any clinical trial of investigational therapies or medical devices.
Exceeding pre-defined laboratory parameters for Triglycerides, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), International normalised ratio (INR), Albumin, Urine albumin-creatinine ratio (uACR) or Glycosylated Hemoglobin (HbA1c).
History of drug abuse within the 12 months prior to Day 1 or evidence of such abuse as indicated by laboratory assays conducted at Screening.
History of hypersensitivity (such as anaphylaxis or hepatotoxicity) to study intervention and/or its excipients, drugs of similar biological class, FGF21 protein analogs, Fc-fusion proteins, or other protein-based therapeutics.
Overt hepatic encephalopathy (West Haven grade \>=2).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fort Worth?

Yes, this clinical trial (NCT07791043) has an active research site in Fort Worth, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Liver Diseases, Alcoholic Treatment Options in Fort Worth, TX

If you're searching for liver diseases, alcoholic treatment options in Fort Worth, TX, this clinical trial (NCT07791043) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fort Worth research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced liver diseases, alcoholic specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all liver diseases, alcoholic clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Fort Worth, TX

See all ankylosing spondylitis clinical trials recruiting in Fort Worth — not just this study.

Browse Ankylosing Spondylitis Trials in Fort Worth →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsLiver Disease TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Fort Worth?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Fort Worth, TX